After confining research deals that could potentially be worth billions in November, big pharma Bayer is investigating this internally as it brings in the changes. In a huge re-structuring, Bayer reports it will be combining its pharma R&D unit under one roof and under one leader in an attempt to shake things up like its competitor European pharma Novartis did in 2016.
Joerg Moeller, currently head of development at Bayer’s pharmaceuticals division, will be taking the reigns and will officially be the new head of R&D, and will begin on New Year’s Day.
Andreas Busch, the head of drug discovery within the pharmaceuticals division of Bayer, will be leaving for “another company,” the company stated but would not say which one specifically. He’s had that role since 2014 and started at Bayer back in the early 1990s.
The new division will unite all R&D activities for therapeutic areas as a whole, within the company’s pharmaceutical division, which includes gynecology, hematology, oncology and cardiology research.
“The combined organization will enable us to seamlessly steer all the important activities of Research and Development, with a single objective to further enhance the delivery of much needed new treatment options to patients,” stated Dieter Weinand, president of Bayer’s pharmaceuticals division.
“Joerg has an exceptional track record of bringing new medicines to patients, which have the potential to increase their quality of life and address serious medical conditions, and I trust that our team will be even more successful in doing so together under his leadership. At the same time, we thank Andreas Busch for all his valuable contributions to our company and wish him much success in his future endeavors.”
This change emerges in the same month that Bayer has been making large wages in R&D, coughing up $400 million (€340 million) a few weeks back and injecting a potential $1 billion more on the table to buy into Loxo Oncology’s tropomyosin receptor kinase inhibitor franchise.